Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal

 
• By John Davis

Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.

Hand Shake
A significant agreement for both companies. • Source: Shutterstock

More from Immuno-oncology

More from Anticancer